Management of oral anticoagulant therapy in the real practice of an anticoagulation clinic: Focus on atrial fibrillation

Daniela Poli, Emilia Antonucci, Alessandra Lombardi, Emanuele Cecchi, Gian Franco Gensini, Rosanna Abbate, Domenico Prisco

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Oral anticoagulant treatment (OAT) is increasingly used for preventing venous thromboembolic and cardiovascular disease. Our study was aimed to evaluate the efficacy and safety of OAT management in a real-practice situation, in particular in non-valvular atrial fibrillation (NVAF) patients. Among 1596 consecutive unselected patients (follow-up, 3364 patient-years) referring to the Anticoagulation Clinic, 558 (follow-up, 958 patient-years) suffered from NVAF. Total bleeding events were recorded in 39/558 NVAF patients (rate, 4.2/100 patient-years) and in 132/1038 of all other patients (rate, 5.4/100 patient-years) (P <0.003). The rate of major bleeding and thrombotic complications was not different between NVAF patients and all the other patients. Considering NVAF patients, the rate of major bleeding was slightly higher in females than in males (P = 0.06). NVAF females showed a higher rate of stroke than males (P = 0.004). In NVAF patients the rate of bleeding complications was not different in relation to age; instead, total and major thrombotic events occurred more frequently in patients ≥ 75 years than in younger patients (P = 0.05 and P = 0.01, respectively). NVAF patients on OAT show a low rate of complications. However, females show a trend to higher risk of bleeding complications and suffered more frequently from stroke with respect to males in spite of therapy.

Original languageEnglish
Pages (from-to)491-494
Number of pages4
JournalBlood Coagulation and Fibrinolysis
Volume16
Issue number7
Publication statusPublished - Oct 2005

Fingerprint

Anticoagulants
Atrial Fibrillation
Therapeutics
Hemorrhage
Stroke
Cardiovascular Diseases

Keywords

  • Atrial fibrillation
  • Bleeding
  • Oral anticoagulant therapy
  • Thrombotic complications

ASJC Scopus subject areas

  • Hematology

Cite this

Poli, D., Antonucci, E., Lombardi, A., Cecchi, E., Gensini, G. F., Abbate, R., & Prisco, D. (2005). Management of oral anticoagulant therapy in the real practice of an anticoagulation clinic: Focus on atrial fibrillation. Blood Coagulation and Fibrinolysis, 16(7), 491-494.

Management of oral anticoagulant therapy in the real practice of an anticoagulation clinic : Focus on atrial fibrillation. / Poli, Daniela; Antonucci, Emilia; Lombardi, Alessandra; Cecchi, Emanuele; Gensini, Gian Franco; Abbate, Rosanna; Prisco, Domenico.

In: Blood Coagulation and Fibrinolysis, Vol. 16, No. 7, 10.2005, p. 491-494.

Research output: Contribution to journalArticle

Poli, D, Antonucci, E, Lombardi, A, Cecchi, E, Gensini, GF, Abbate, R & Prisco, D 2005, 'Management of oral anticoagulant therapy in the real practice of an anticoagulation clinic: Focus on atrial fibrillation', Blood Coagulation and Fibrinolysis, vol. 16, no. 7, pp. 491-494.
Poli, Daniela ; Antonucci, Emilia ; Lombardi, Alessandra ; Cecchi, Emanuele ; Gensini, Gian Franco ; Abbate, Rosanna ; Prisco, Domenico. / Management of oral anticoagulant therapy in the real practice of an anticoagulation clinic : Focus on atrial fibrillation. In: Blood Coagulation and Fibrinolysis. 2005 ; Vol. 16, No. 7. pp. 491-494.
@article{37c2c07392ee4727abd83bc40fa5641f,
title = "Management of oral anticoagulant therapy in the real practice of an anticoagulation clinic: Focus on atrial fibrillation",
abstract = "Oral anticoagulant treatment (OAT) is increasingly used for preventing venous thromboembolic and cardiovascular disease. Our study was aimed to evaluate the efficacy and safety of OAT management in a real-practice situation, in particular in non-valvular atrial fibrillation (NVAF) patients. Among 1596 consecutive unselected patients (follow-up, 3364 patient-years) referring to the Anticoagulation Clinic, 558 (follow-up, 958 patient-years) suffered from NVAF. Total bleeding events were recorded in 39/558 NVAF patients (rate, 4.2/100 patient-years) and in 132/1038 of all other patients (rate, 5.4/100 patient-years) (P <0.003). The rate of major bleeding and thrombotic complications was not different between NVAF patients and all the other patients. Considering NVAF patients, the rate of major bleeding was slightly higher in females than in males (P = 0.06). NVAF females showed a higher rate of stroke than males (P = 0.004). In NVAF patients the rate of bleeding complications was not different in relation to age; instead, total and major thrombotic events occurred more frequently in patients ≥ 75 years than in younger patients (P = 0.05 and P = 0.01, respectively). NVAF patients on OAT show a low rate of complications. However, females show a trend to higher risk of bleeding complications and suffered more frequently from stroke with respect to males in spite of therapy.",
keywords = "Atrial fibrillation, Bleeding, Oral anticoagulant therapy, Thrombotic complications",
author = "Daniela Poli and Emilia Antonucci and Alessandra Lombardi and Emanuele Cecchi and Gensini, {Gian Franco} and Rosanna Abbate and Domenico Prisco",
year = "2005",
month = "10",
language = "English",
volume = "16",
pages = "491--494",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Management of oral anticoagulant therapy in the real practice of an anticoagulation clinic

T2 - Focus on atrial fibrillation

AU - Poli, Daniela

AU - Antonucci, Emilia

AU - Lombardi, Alessandra

AU - Cecchi, Emanuele

AU - Gensini, Gian Franco

AU - Abbate, Rosanna

AU - Prisco, Domenico

PY - 2005/10

Y1 - 2005/10

N2 - Oral anticoagulant treatment (OAT) is increasingly used for preventing venous thromboembolic and cardiovascular disease. Our study was aimed to evaluate the efficacy and safety of OAT management in a real-practice situation, in particular in non-valvular atrial fibrillation (NVAF) patients. Among 1596 consecutive unselected patients (follow-up, 3364 patient-years) referring to the Anticoagulation Clinic, 558 (follow-up, 958 patient-years) suffered from NVAF. Total bleeding events were recorded in 39/558 NVAF patients (rate, 4.2/100 patient-years) and in 132/1038 of all other patients (rate, 5.4/100 patient-years) (P <0.003). The rate of major bleeding and thrombotic complications was not different between NVAF patients and all the other patients. Considering NVAF patients, the rate of major bleeding was slightly higher in females than in males (P = 0.06). NVAF females showed a higher rate of stroke than males (P = 0.004). In NVAF patients the rate of bleeding complications was not different in relation to age; instead, total and major thrombotic events occurred more frequently in patients ≥ 75 years than in younger patients (P = 0.05 and P = 0.01, respectively). NVAF patients on OAT show a low rate of complications. However, females show a trend to higher risk of bleeding complications and suffered more frequently from stroke with respect to males in spite of therapy.

AB - Oral anticoagulant treatment (OAT) is increasingly used for preventing venous thromboembolic and cardiovascular disease. Our study was aimed to evaluate the efficacy and safety of OAT management in a real-practice situation, in particular in non-valvular atrial fibrillation (NVAF) patients. Among 1596 consecutive unselected patients (follow-up, 3364 patient-years) referring to the Anticoagulation Clinic, 558 (follow-up, 958 patient-years) suffered from NVAF. Total bleeding events were recorded in 39/558 NVAF patients (rate, 4.2/100 patient-years) and in 132/1038 of all other patients (rate, 5.4/100 patient-years) (P <0.003). The rate of major bleeding and thrombotic complications was not different between NVAF patients and all the other patients. Considering NVAF patients, the rate of major bleeding was slightly higher in females than in males (P = 0.06). NVAF females showed a higher rate of stroke than males (P = 0.004). In NVAF patients the rate of bleeding complications was not different in relation to age; instead, total and major thrombotic events occurred more frequently in patients ≥ 75 years than in younger patients (P = 0.05 and P = 0.01, respectively). NVAF patients on OAT show a low rate of complications. However, females show a trend to higher risk of bleeding complications and suffered more frequently from stroke with respect to males in spite of therapy.

KW - Atrial fibrillation

KW - Bleeding

KW - Oral anticoagulant therapy

KW - Thrombotic complications

UR - http://www.scopus.com/inward/record.url?scp=29144486675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144486675&partnerID=8YFLogxK

M3 - Article

C2 - 16175008

AN - SCOPUS:29144486675

VL - 16

SP - 491

EP - 494

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 7

ER -